ClinicalTrials.gg
Status unknownNCT05689632Updated Jan 19, 2023

Vitamins D and K Effects on Vascular Function in Obese Adults.

An interventional study of Vitamin D3 + K2-MK7 and Placebo in Obesity and Vitamin D3 Deficiency, sponsored by Hospital Universitario Pedro Ernesto. Status unknown at 1 site in Brazil. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-19.

Sponsored by Hospital Universitario Pedro Ernesto · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jul 2022, registered Jan 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Study summary

A prospective, randomized, placebo-controlled, double-blind study that aims to evaluate the effects of combined vitamin D3 and K2-MK7 supplementation on vascular function, sympathetic tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese adults and deficient or insufficient serum levels of vitamin D.

Read the detailed description

Overweight and obesity are public health issues of epidemic proportions nowadays. They constitute risk factors for several chronic diseases with vascular, metabolic, and inflammatory changes. Adequate serum levels of vitamin D are correlated with good cardiovascular and metabolic health, since its deficiency and insufficiency (highly prevalent in obesity) have an inverse correlation. Likewise, vitamin K, especially K2, is related to the reduction of arterial stiffness, suppression of the inflammation in the vascular wall, favorable action on the lipid profile, whereas insufficiency is related to increased cardiovascular risk. The combined use of vitamin D and K aiming to reduce cardiovascular risk has been studied, however, the results of randomized clinical trials are still controversial. This prospective, randomized, placebo-controlled, double-blind trial aims to evaluate the effect of supplementation of vitamins D3 and K2-MK7 on vascular function, sympathetic tone, metabolic biomarkers and inflammatory factors in a population of overweight or obese adults and serum levels of deficient or insufficient vitamin D. Individuals of both sexes, aged between 40 and 70 years, body mass index (BMI) ≥ 25 and \< 40 kg/m² and vitamin 25OHD3 \<30 ng/ml will be randomized into 3 groups (A/B/C) to receive supplementation (Placebo/VitD3 7000 IU/VitD3 7000IU+K2-MK7-180mcg) daily for 16 weeks. Individuals will be rated at 4 visits namely:

  • V0 screening according to inclusion and exclusion criteria; clinical, anthropometry and electrical bioimpedance, laboratory and vascular evaluation before supplementation;
  • V1 supplementation begins;
  • V2 after 8 weeks;
  • V3 at the end of the intervention. The laboratory evaluation consists of blood count, biochemistry, electrolytes, glucose, lipid, liver and thyroid profiles, vitamin D3 and parathyroid hormone, in addition to the urinary excretion of calcium and creatinine. Sympathetic tone is assessed by a frequency meter (Polar® Verity Sense), arterial stiffness by measuring the pulse wave velocity by oscillometry (Mobil-O-Graph®) and endothelium function by measuring post-occlusion microvascular reactivity using laser speckle contrast image-LSCI.
02

Conditions studied

  • Obesity
  • Vitamin D3 Deficiency

Browse trials for

Keywords

  • Obesity
  • Vitamin D3 Deficiency
  • Vitamin K
  • Sympathetic tonus
  • Endothelial dysfunction
  • Arterial stiffness
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 100 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Hospital Universitario Pedro Ernesto is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Vitamin D deficiency;
  • Vitamin D insufficiency;
  • Obesity;
  • Overweight;

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus;
  • Arterial coronary disease;
  • Beta blocker use;
  • cancer;
  • ESRD;
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    Placebo - Medium-chain triglyceride

    Dietary Supplement: Placebo

  • Active comparator
    Vitamin D3

    Vitamin D3 - 7000 IU daily

    Dietary Supplement: Vitamin D3

  • Experimental
    Vitamin D3 + K2-MK7

    Vitamin D3 - 7000 IU + Vitamin K2-MK7 180mcg combined, daily

    Dietary Supplement: Vitamin D3 + K2-MK7

Interventions

06

What researchers measure

Primary outcomes

  1. Microvascular reactivity

    A laser speckle contrast imaging system with a laser wavelength of 785 nm system will measure non-invasively real time cutaneous microvascular flow changes in the forearm. For the post occlusive reactive hyperemia test, arterial occlusion will be performed with suprasystolic pressure (50 mmHg above the systolic arterial pressure) using a sphygmomanometer applied to the arm of the subject over three minutes. Peak skin flow will be measured after pressure release.

    Time frame: 150 minutes

Secondary outcomes

  1. Central blood pressure

    Central systolic blood pressure, diastolic blood pressure, mean arterial pressure and pulse pressure before and after intervention and their potential effects on changes in subendocardial viability ratio and ejection duration after intervention with beetroot juice and water.

    Time frame: 150 minutes

07

Study locations

1 of 1 sites recruiting
  • Rio de Janeiro State University
    Rio de Janeiro, 20551-030, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — No plans to share IPD with other researchers

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05689632
Lead sponsor
Hospital Universitario Pedro Ernesto
Collaborators
Rio de Janeiro State Research Supporting Foundation (FAPERJ), Conselho Nacional de Desenvolvimento Científico e Tecnológico
Responsible party
Mario Fritsch Neves (FULL PROFESSOR, Hospital Universitario Pedro Ernesto) — Principal investigator
First posted
Jan 19, 2023
Start date
Jul 15, 2022
Primary completion
Jul 15, 2023 (estimated)
Completion
Nov 15, 2023 (estimated)
Last update
Jan 19, 2023

Study contacts

Adriana C Faria, MD
Contact
afmenie@gmail.com
5521999834054
Mario F Neves, MD, PhD
Contact
mariofneves@gmail.com
Adriana C Faria, MD
principal investigator · State University of Rio de Janeiro
Mario F Neves, MD, PhD
study director · State University of Rio de Janeiro

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cholecalciferol · Menaquinone 7

Start the discussion